Related Experiment Video

Updated: Feb 23, 2026

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research
06:25

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research

Published on: March 29, 2024

1.6K

CSF-1R Inhibitor Development: Current Clinical Status

Florent Peyraud1,2, Sophie Cousin1,2, Antoine Italiano3,4

  • 1Early Phase Trials Unit, Institut Bergonié, 229 Cours de l'Argonne, 33000, Bordeaux, France.

Current Oncology Reports
|September 7, 2017
PubMed
Abstract

Insights

Targeting colony-stimulating factor 1 receptor (CSF-1R) shows promise for treating cancers and pigmented villonodular synovitis (PVNS). While in vivo antitumor activity is limited, CSF-1R inhibitors offer a promising immunotherapy approach for PVNS.

Area of Science:

  • Immunology
  • Oncology
  • Pathology

Background:

  • Colony-stimulating factor 1 receptor (CSF-1R) and its ligands regulate tumor-associated macrophages, impacting tumorigenesis and immune suppression.
  • The CSF-1R/CSF-1 axis is implicated in the pathogenesis of pigmented villonodular synovitis (PVNS).
  • Advanced solid tumors and PVNS present significant unmet therapeutic needs.

Purpose of the Study:

  • To review the role of CSF-1R in tumorigenesis and PVNS.
  • To evaluate current therapeutic strategies targeting CSF-1R.
  • To explore future combination therapies involving CSF-1R inhibition.

Main Methods:

  • Review of preclinical and clinical studies on CSF-1R inhibitors.
  • Analysis of in vitro and in vivo data for solid tumors.
  • Assessment of clinical trial outcomes for PVNS.

Main Results:

  • CSF-1R inhibition shows limited in vivo antitumor activity in solid tumors.
  • CSF-1R inhibitors have demonstrated promising initial outcomes in clinical trials for PVNS.
  • Blocking CSF-1/CSF-1R signaling is a viable immunotherapy strategy.

Conclusions:

  • Targeting CSF-1R is a promising approach for PVNS and potentially for solid tumors.
  • Further research into combination therapies is warranted.
  • CSF-1R inhibitors represent a novel therapeutic avenue.
Keywords:
CSF-1CSF-1R inhibitorCSF1-RDiffuse-type giant-cell tumorPigmented villonodular synovitisSolid tumorsTargeted therapyTumor-associated macrophages

More Related Videos

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

10.5K
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.8K

Related Concept Videos

Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
4.2K
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.1K
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
573
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.1K
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
30